Involvement of carnitine/organic cation transporter OCTN1/SLC22A4 in gastrointestinal absorption of metformin

Journal of Pharmaceutical Sciences

Volumn 102, Issue 9, 2013, Pages 3407-3417

  Nakamichi, Noritaka ^a   Shima, Hiroyo ^a   Asano, Satoshi ^a   Ishimoto, Takahiro ^a   Sugiura, Tomoko ^a   Matsubara, Kazuki ^a   Kusuhara, Hiroyuki ^b   Sugiyama, Yuichi ^b   Sai, Yoshimichi ^a   Miyamoto, Ken Ichi ^a   Tsuji, Akira ^a   Kato, Yukio ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

ADME; Drug transport; Oral absorption; Organic cation transporter; Pharmacokinetics; Renal excretion

Indexed keywords

CARNITINE; METFORMIN; ORGANIC CATION TRANSPORTER; ORGANIC CATION TRANSPORTER OCTN1; ORGANIC CATION TRANSPORTER SLC22A4; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; APICAL MEMBRANE; ARTICLE; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG ABSORPTION; DRUG HALF LIFE; DRUG UPTAKE; GASTROINTESTINAL ABSORPTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTESTINE EPITHELIUM CELL; KNOCKOUT GENE; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SMALL INTESTINE;

ADME; DRUG TRANSPORT; ORAL ABSORPTION; ORGANIC CATION TRANSPORTER; PHARMACOKINETICS; RENAL EXCRETION;

ANIMALS; BIOLOGICAL TRANSPORT, ACTIVE; CACO-2 CELLS; CARRIER PROTEINS; HEK293 CELLS; HUMANS; HYPOGLYCEMIC AGENTS; INTESTINAL ABSORPTION; INTESTINE, SMALL; MALE; MEMBRANE PROTEINS; METFORMIN; MICE; MICE, KNOCKOUT;

EID: 84881614259     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23595     Document Type: Article

References (34)

1. Belda-Iniesta C, Pernía O, Simó R. 2011. Metformin: A new option in cancer treatment. Clin Transl Oncol 13:363-367.
2. Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F. 2012. Cellular and molecular mechanisms of metformin: An overview. Clin Sci 122:253-270.
3. Kusuhara H, Ito S, Kumagai Y, Jiang M, Shiroshita T, Moriyama Y, Inoue K, Yuasa H, Sugiyama Y. 2011. Effects of a MATE protein inhibitor, pyrimethamine, on the renal elimination of metformin at oral microdose and at therapeutic dose in healthy subjects. Clin Pharmacol Ther 89:837-844.
4. Shu Y, Sheardown SA, Brown C, Owen RP, Zhang S, Castro RA, Ianculescu AG, Yue L, Lo JC, Burchard EG, Brett CM, Giacomini KM. 2007. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest 117:1422-1431.
5. Song N, Li Q, Liu C. 2006. Intestinal permeability of metformin using single-pass intestinal perfusion in rats. World J Gastroenterol 12:4064-4070.
6. Toyama K, Yonezawa A, Masuda S, Osawa R, Hosokawa M, Fujimoto S, Inagaki N, Inui K, Katsura T. 2012. Loss of multidrug and toxin extrusion 1 (MATE1) is associated with metformin-induced lactic acidosis. Br J Pharmacol 166:1183-1191.
7. Tsuda M, Terada T, Mizuno T, Katsura T, Shimakura J, Inui K. 2009. Targeted disruption of the multidrug and toxin extrusion 1 (mate1) gene in mice reduces renal secretion of metformin. Mol Pharmacol 75:1280-1286.
8. Shugarts S, Benet LZ. 2009. The role of transporters in the pharmacokinetics of orally administered drugs. Pharm Res 26:2039-2054.
9. Zhou M, Xia L, Wang J. 2007. Metformin transport by a newly cloned proton-stimulated organic cation transporter (plasma membrane monoamine transporter) expressed in human intestine. Drug Metab Dispos 35:1956-1962.
10. Christensen MM, Brasch-Andersen C, Green H, Nielsen F, Damkier P, Beck-Nielsen H, Brosen K. 2011. The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c. Pharmacogenet Genomics 21:837-850.
11. +/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. J Am Soc Nephrol 17:2127-2135.
12. Gründemann D, Harlfinger S, Golz S, Geerts A, Lazar A, Berkels R, Jung N, Rubbert A, Schömig E. 2005. Discovery of the ergothioneine transporter. Proc Natl Acad Sci USA 102:5256-5261.
13. Tamai I, Yabuuchi H, Nezu J, Sai Y, Oku A, Shimane M, Tsuji A. 1997. Cloning and characterization of a novel human pH-dependent organic cation transporter, OCTN1. FEBS Lett 419:107-111.
14. Yabuuchi H, Tamai I, Nezu J, Sakamoto K, Oku A, Shimane M, Sai Y, Tsuji A. 1999. Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations. J Pharmacol Exp Ther 289:768-773.
15. Sugiura T, Kato S, Shimizu T, Wakayama T, Nakamichi N, Kubo Y, Iwata D, Suzuki K, Soga T, Asano M, Iseki S, Tamai I, Tsuji A, Kato Y. 2010. Functional expression of carnitine/organic cation transporter OCTN1/SLC22A4 in mouse small intestine and liver. Drug Metab Dispos 38:1665-1672.
16. Kato Y, Kubo Y, Iwata D, Kato S, Sudo T, Sugiura T, Kagaya T, Wakayama T, Hirayama A, Sugimoto M, Sugihara K, Kaneko S, Soga T, Asano M, Tomita M, Matsui T, Wada M, Tsuji A. 2010. Gene knockout and metabolome analysis of carnitine/organic cation transporter OCTN1 (SLC22A4). Pharm Res 27:832-840.
17. Sugiura T, Otake T, Shimizu T, Wakayama T, Silver DL, Utsumi R, Nishimura T, Iseki S, Nakamichi N, Kubo Y, Tsuji A, Kato Y. 2010. PDZK1 regulates organic anion transporting polypeptide Oatp1a in mouse small intestine. Drug Metab Pharmacokinet 25:588-598.
18. Nishimura T, Kubo Y, Kato Y, Sai Y, Ogihara T, Tsuji A. 2007. Characterization of the uptake mechanism for a novel loop diuretic, M17055, in Caco-2 cells: Involvement of organic anion transporting polypeptide (OATP)-B. Pharm Res 24:90-98.
19. Graham GG, Punt J, Arora M, Day RO, Doogue MP, Duong JK, Furlong TJ, Greenfield JR, Greenup LC, Kirkpatrick CM, Ray JE, Timmins P, Williams KM. 2011. Clinical pharmacokinetics of metformin. Clin Pharmacokinet 50:81-98.
20. Yoon H, Cho HY, Yoo HD, Kim SM, Lee YB. 2013. Influences of organic cation transporter polymorphisms on the population pharmacokinetics of metformin in healthy subjects. AAPS J 15:571-580.
21. Grigat S, Harlfinger S, Pal S, Striebinger R, Golz S, Geerts A, Lazar A, Schömig E, Gründemann D. 2007. Probing the substrate specificity of the ergothioneine transporter with methimazole, hercynine, and organic cations. Biochem Pharmacol 74:309-316.
22. Pochini L, Scalise M, Galluccio M, Amelio L, Indiveri C. 2011. Reconstitution in liposomes of the functionally active human OCTN1 (SLC22A4) transporter overexpressed in Escherichia coli. Biochem J 439:227-233.
23. Pochini L, Scalise M, Galluccio M, Pani G, Siminovitch KA, Indiveri C. 2012. The human OCTN1 (SLC22A4) reconstituted in liposomes catalyzes acetylcholine transport which is defective in the mutant L503F associated to the Crohn's disease. Biochim Biophys Acta 1818:559-565.
24. Urban TJ, Brown C, Castro RA, Shah N, Mercer R, Huang Y, Brett CM, Burchard EG, Giacomini KM. 2008. Effects of genetic variation in the novel organic cation transporter, OCTN1, on the renal clearance of gabapentin. Clin Pharmacol Ther 83:416-421.
25. Tzvetkov MV, Vormfelde SV, Balen D, Meineke I, Schmidt T, Sehrt D, Sabolić I, Koepsell H, Brockmöller J. 2009. The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. Clin Pharmacol Ther 86:299-306.
26. Tamai I, Nakanishi T, Kobayashi D, China K, Kosugi Y, Nezu J, Sai Y, Tsuji A. 2004. Involvement of OCTN1 (SLC22A4) in pH-dependent transport of organic cations. Mol Pharm 1:57-66.
27. Stepensky D, Friedman M, Raz I, Hoffman A. 2002. Pharmacokinetic-pharmacodynamic analysis of the glucose-lowering effect of metformin in diabetic rats reveals first-pass pharmacodynamic effect. Drug Metab Dispos 30:861-868.
28. UK Prospective Diabetes Study (UKPDS) Group. 1998. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854-865.
29. Mamputu JC, Wiernsperger NF, Renier G. 2003. Antiatherogenic properties of metformin: The experimental evidence. Diabetes Metab 29:6S71-6S76.
30. Messaoudi SEI, Rongen GA, de Boer RA, Riksen NP. 2011. The cardioprotective effects of metformin. Curr Opin Lipidol 22:445-453.
31. Iwata D, Kato Y, Wakayama T, Sai Y, Kubo Y, Iseki S, Tsuji A. 2008. Involvement of carnitine/organic cation transporter OCTN2 (SLC22A5) in distribution of its substrate carnitine to the heart. Drug Metab Pharmacokinet 23:207-215.
32. Grube M, Ameling S, Noutsias M, Köck K, Triebel I, Bonitz K, Meissner K, Jedlitschky G, Herda LR, Reinthaler M, Rohde M, Hoffmann W, Kühl U, Schultheiss HP, Völker U, Felix SB, Klingel K, Kandolf R, Kroemer HK. 2011. Selective regulation of cardiac organic cation transporter novel type 2 (OCTN2) in dilated cardiomyopathy. Am J Pathol 178:2547-2559.
33. McBride BF, Yang T, Liu K, Urban TJ, Giacomini KM, Kim RB, Roden DM. 2009. The organic cation transporter, OCTN1, expressed in the human heart, potentiates antagonism of the HERG potassium channel. J Cardiovasc Pharmacol 54:63-71.
34. Wang DS, Kusuhara H, Kato Y, Jonker JW, Schinkel AH, Sugiyama Y. 2003. Involvement of organic cation transporter 1 in the lactic acidosis caused by metformin. Mol Pharmacol 63:844-848.